MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Yahoo Finance · Sep 30, 2026 · Mink Therapeutics Inc (INKT)
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invaria
Not investment advice. Headline and summary only, not a full reprint.